Hims & Hers GLP-1 partnership sparks new weight-loss boom

What does the Hims & Hers GLP-1 partnership include?

Hims & Hers Health, Inc. has begun offering multiple GLP-1 options from Novo Nordisk, centering on Wegovy and Ozempic, to eligible customers through its online platform. The rollout covers Wegovy (semaglutide) injections at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg, as well as oral Wegovy pills in 1.5 mg, 4 mg, 9 mg and 25 mg dosages, with a 7.2 mg injection expected later. Wegovy is currently the only FDA-approved GLP-1 medication specifically indicated for weight loss.

Ozempic (semaglutide) injection pens at 0.25 mg, 0.5 mg, 1 mg and 2 mg will also be available, but only for patients with Type 2 diabetes based on individual clinical judgment, since Ozempic itself is not approved as a weight-loss drug. Pricing for GLP-1 treatments via the Hims & Hers GLP-1 partnership starts at $149 per month, excluding membership fees. Eligibility and prescriptions are determined by independent providers on the platform, who will decide whether switching patients from compounded GLP-1s to branded products is clinically appropriate.

How does the new Hims & Hers membership work?

Alongside the Hims & Hers GLP-1 partnership, the company is launching a dedicated weight-loss membership aimed at bundling clinical support with drug access. The subscription starts at $39 for the first month and rises to $149 per month thereafter, with medication costs billed separately and potentially payable via HSA or FSA plans. Every member receives 24/7 access to providers, personalized nutrition guidance, recurring clinical check-ins and access to the Hers Weight Loss peer community.

Hims & Hers positions this offering as a comprehensive program rather than a pure prescription service, integrating lifestyle support with GLP-1 therapy. Customers already using the platform’s compounded GLP-1 products will be educated on the expanded lineup of FDA-approved options and, where medically appropriate, transitioned to the new Novo Nordisk therapies. For a narrower group whose needs cannot be met with branded drugs, the company plans to keep limited access to compounded GLP-1s, depending on provider assessment.

How are markets reacting to the Hims & Hers GLP-1 partnership?

On Thursday, HIMS traded around $20.63, down roughly 1% from the prior close, even as the Hims & Hers GLP-1 partnership formally went live. The stock remains well below recent intraday peaks near the mid-$20s but has rallied sharply since legal uncertainties earlier this year pressured shares. A prior lawsuit from Novo Nordisk over compounded GLP-1 products and an FDA communication about active pharmaceutical ingredients triggered a more than 17% single-day drop in February, which had weighed heavily on sentiment.

That overhang has eased as Hims & Hers and Novo Nordisk shifted from adversaries to collaborators, enabling the telehealth company to distribute branded GLP-1 therapies at scale. Research desks such as Zacks Investment Research have highlighted that Hims & Hers’ subscriber growth, product expansion and integrated digital ecosystem could justify higher valuations if execution on weight loss and other verticals continues. The move into approved GLP-1s adds a new, potentially higher-margin growth driver at a time when Wall Street is closely tracking the broader obesity drug theme across the NASDAQ and S&P 500 health names.

How does Hims & Hers stack up against rivals?

For U.S. investors, the Hims & Hers GLP-1 partnership sits at the intersection of digital health and obesity therapeutics, putting the company in indirect competition with telehealth peers and big pharma alike. Unlike Apple or NVIDIA, which are reshaping consumer tech and AI, Hims & Hers is focused on building a consumer-facing healthcare brand that normalizes access to treatments once confined to specialist clinics. In weight loss, the company’s offering complements Novo Nordisk’s scale rather than competing with it, while differentiating itself from pure-play GLP-1 manufacturers by owning the front-end patient relationship.

Within digital health, investors often compare Hims & Hers to platforms such as Doximity and other telemedicine providers listed on the NYSE and NASDAQ. Recent analysis contrasting Hims & Hers with peers has pointed to its subscription-heavy model, direct-to-consumer marketing engine and rapid expansion into new categories as key drivers of potential multiple expansion. For now, Hims & Hers remains a mid-cap growth story outside the S&P 500, but its ability to capture recurring GLP-1 revenue could move it closer into the sights of larger healthcare and tech investors tracking high-growth, consumer-oriented platforms similar to Tesla’s disruptive profile in autos.

What are the key risks around the GLP-1 strategy?

Despite the bullish narrative around the Hims & Hers GLP-1 partnership, risks remain material. Regulatory scrutiny of compounded GLP-1 drugs has already led to volatility, and Hims & Hers is now more exposed to supply, pricing and reimbursement dynamics tied to Novo Nordisk’s pipeline. Any changes in FDA guidance, insurance coverage trends or competitive launches from other obesity drugs could impact volumes or margin assumptions for the subscription program.

Legal and governance risks are also in focus. The Schall Law Firm recently announced a securities fraud investigation related to earlier disclosures and the GLP-1 business, inviting shareholders who suffered losses to join the action. At the same time, insider activity — including pre-planned share sales by the company’s CFO — is being closely monitored by investors who are wary of management de-risking into strength. While several bullish research notes from firms like Zacks underline upside potential, Wall Street will want to see sustained execution, transparent reporting and stable regulatory footing before assigning premium multiples.

Related Coverage

Investors tracking insider dynamics alongside the Hims & Hers GLP-1 partnership may want to read Hims & Hers insider transactions Warning as GLP-1 bets grow, which examines whether recent stock sales by executives are signaling caution just as the company doubles down on obesity drugs. For a broader look at how big pharma is repositioning for post-patent life, the article Merck Terns Acquisition $6.7B Surge as Keytruda Cliff Nears explores whether Merck’s latest oncology deal can offset a looming revenue cliff, offering useful context on how established players are betting on high-growth therapeutics.